At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 382 enrolled
Drug / intervention
MenACWY-CRM197 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants
In Brief
A Phase 2 clinical trial evaluating MenACWY-CRM197 and Blood test for Meningococcal Disease. Completed, enrolled 382 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Disease
CountriesCanada, United Kingdom
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartFeb 2008
Primary CompletionJul 2010
Study CompletionSep 2010
TodayJul 2026
First PostedJan 28, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJul 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.4 years ago
Interventions
MenACWY-CRM197biological
Blood test, 40-months and 60-months children
Blood testbiological
Blood test, 40-months and 60-months children